Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Research & Development came in at $87.9 million in Q1 2026, down 32.2% YoY from $129.6 million in Q1 2025, and down 8.38% on a QoQ basis from $95.9 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Research & Development data on file, last reported at $87.9 million in Q1 2026.
- Quarterly Research & Development fell 32.2% year-over-year to $87.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $433.5 million (up 15.15% YoY) and the FY2025 annual result came in at $475.3 million, up 51.16% from the prior year.
- Research & Development declined to $87.9 million in Q1 2026, from $95.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $129.6 million in Q1 2025 to a low of $32.4 million in Q1 2022.
- A 5-year average of $75.0 million and a median of $70.0 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2025 — Research & Development surged 91.88% — and 2026, when it plunged 32.2%.
- Tracing RXRX's Research & Development over 5 years: stood at $44.0 million in 2022, then soared by 57.99% to $69.5 million in 2023, then jumped by 41.52% to $98.3 million in 2024, then fell by 2.43% to $95.9 million in 2025, then dropped by 8.38% to $87.9 million in 2026.
- The last three Research & Development figures came in at $87.9 million (Q1 2026), $95.9 million (Q4 2025), and $121.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 89.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.61 Mn |
| Mar 31, 2026 | 87.90 Mn |
| Dec 31, 2025 | 95.94 Mn |
| Sep 30, 2025 | 121.06 Mn |
| Jun 30, 2025 | 128.64 Mn |
| Mar 31, 2025 | 129.63 Mn |
| Dec 31, 2024 | 98.33 Mn |
| Sep 30, 2024 | 74.60 Mn |
| Jun 30, 2024 | 73.93 Mn |
| Mar 31, 2024 | 67.56 Mn |
| Dec 31, 2023 | 69.48 Mn |
| Sep 30, 2023 | 70.01 Mn |
| Jun 30, 2023 | 55.06 Mn |
| Mar 31, 2023 | 46.68 Mn |
| Dec 31, 2022 | 43.98 Mn |
| Sep 30, 2022 | 40.84 Mn |
| Jun 30, 2022 | 38.44 Mn |
| Mar 31, 2022 | 32.44 Mn |
| Dec 31, 2021 | 48.29 Mn |
| Sep 30, 2021 | 33.25 Mn |